Investors show interest in emerging areas such as fertility, psychedelics, gene therapy and heavy metal treatments, though these often face opaque and rapidly evolving regulatory challenges. Shifts in government policy and enforcement, especially regarding drug manufacturing, clinical trials and global supply chains, are shaping strategic decision-making for investors and companies, making life sciences an area in which private equity can deliver support to improve patient care and treatment options. The recurring themes across panels highlight a sector undergoing transformation — driven by regulation, innovation and shifting incentives — in which deep understanding of both compliance and niche opportunity is critical.
Read the full article: Insights from the 21st Annual McGuireWoods Healthcare Private Equity and Finance Conference: Life Sciences Investments //
Source: https://www.mcguirewoods.com/client-resources/alerts/2025/6/insights-from-the-21st-annual-mcguirewoods-healthcare-private-equity-and-finance-conference-part-4-life-sciences-investments/